Effect of time of administration of concurrent and adjuant temozolamide in glioma

Evaluation of chronotherapy of concomitant and adjuvant temozolamide in high grade glioma patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241207063970N1

Enrollment

Registered

2025-12-05

Start date

2025-12-11

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma, glioblastoma.

Interventions

Intervention 1: AM (Taking temozolamide before 12:00 AM, either simultaneously with radiotherapy (with an interval of 1 hour before radiotherapy) or as an adjuvant). Intervention 2: PM (Taking temozol

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: high grade Glioma based on histopathology and IHC(Grade 3 and 4, grade2 with IDH WT, EGFR amp, TERT mut.)

Exclusion criteria

Exclusion criteria: pregnant patient Breast Feeding patient

Design outcomes

Primary

Measure	Time frame
Objective response rate? progression free survival. Timepoint: 6 month after treatment completion. Method of measurement: MRI and response rate based on RECIST criteria.	—

Secondary

Measure	Time frame
Overal survival. Timepoint: 1 year. Method of measurement: Contact the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Salari

Shahid Beheshti University of Medical Sciences

f.salari1996@gmail.com+98 21 25719

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026